Meso Numismatics Closes Global Stem Cell Group Acquisition
LAS VEGAS, NV, August 18, 2021 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, MSSV is pleased to announce that it has closed its acquisition of Global Stem Cells Group. “We are pleased to have finally been able to close on this acquisition,” said David Christensen, President and CEO of MSSV,” We are now well positioned to enter into the growing global Regenerative Medicine industry.”
Global Stem Cells Group (Global) is a premier Regenerative Medicine company that specializes in cutting edge stem cell research, current clinical applications, and physician training. Global licenses its intellectual property and name to medical professionals around the world providing them with necessary equipment and cellular therapy products needed to perform safe and effective Regenerative medicine related treatments. Global has one of the larges physician membership networks in the world with 29 offices in more than 25 countries. The worldwide Regenerative Medicine industry is a multi billion-dollar industry projected to have double digit annual growth rates over the next decade. For more information on Global Stem Cells Group please follow the link www.stemcellsgroup.com
Please read this press release in conjunction with the 8K that was filed today on www.sec.gov.
MSSV has also renegotiated its June 22, 2021 $10.5M financing, of which $8.2M is earmarked for the Lans Holdings Escrow as per the 8k filed June 24th, 2021, as follows: the warrant maturity has been changed to 7 years instead of 3 years and the warrant shall be locked up for the first 2 years whereas during the lock up period the warrant will not be able to be exercised.
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company’s breadth of business experience and technology team, the Company will continue to help companies grow. Meso has now added bio-technology to it’s portfolio and will continue to grow the company in this new direction.
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company’s breadth of business experience and technology team, the Company will continue to help companies grow.
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Meso Numismatics, Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Meso Numismatics, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
- Published in Press Releases
Global Stem Cells Group has Announced an Agreement with Rokit Healthcare
Global Stem Cells Group announces an agreement with the South Korean biotechnology giant known as Rokit Healthcare to represent the company’s technology in the Latin American market.
The Global Stem Cells Group (GSCG) a world leader in Regenerative Medicine Technologies has signed an agreement with South Korean-based Rokit Healthcare, an esteemed bioprinter manufacturer that is committed to advancing the field of regenerative medicine and bettering the quality of life of people around the world.
The field of bioprinting is an extremely new one, but it shows great promise. Simply, it is the automated, computer aided deposition of bio-materials (which are cells, growth factors, and biocompatible polymers) for the manufacturing of functional human tissues or organs. Growth factors are harvested and used with a proprietary printing technology to create or regenerative damaged or diseased organs. Rokit Healthcare does this primarily through the proliferation of a machine that they dub an ‘organ regenerator’– it looks like a 3D printer, but instead of using plastics to create things, they use cells and materials that will be safe to implant within the human body.
The process of 3D bioprinting human tissues and organs is a revolutionary technology in the field of tissue engineering. One of the major challenges in regenerative medicine research and tissue engineering is mimicking the micro and macro environment of human tissues. In response to this challenge, advances in additive manufacturing have inspired scientists in Korea to develop novel bioprinting technology, for human tissues and organs
With the advancements of 3D printing and regenerative medicine working together, the potential is seemingly limitless for the spreading of bioprinting technology, a process that is known as 4D Printing– and Global Stem Cells Group, in an effort make this revolutionary technology available to patients, has forged an agreement with Rokit Healthcare to promote, and distribute the company’s technology in Latin America-
The Invivo 4D Printer is Rokit Healthcare’s flagship product, and it is one that revolutionizes the application of regenerative medicine and growth factor-based therapies. creating a solution for personalized and improved patient care. By leveraging a combination of 3D and bioprinting technologies, it can better distribute a patient’s autologous tissues and cells, making it an invaluable tool for those that are looking to improve the efficacy of their results, especially for certain dermatological conditions including scarring.
“We’re extremely excited about this new opportunity and look forward to working with Rokit,” Says Benito Novas, CEO of the Global Stem Cells Group, “The Invivo 4D Printer is in a position to turn the practice of regenerative medicine onto its head, and we are planning on creating a training center in Cancun, Mexico exclusively to showcase and instruct other physicians in this cutting-edge technology,”
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for regenerative medicine solutions that adhere to the highest medical standards.
About ROKIT :
ROKIT Healthcare is a global healthcare company that is committed to providing an effective and autologous organ regeneration platform. In order to undertake this daunting task, the company uses proprietary biofabrication technologies that show promise in treating several types of diseases in the field of regenerative medicine. Through the proliferation of 4D bioprinting technology, autologous stem cell technologies, ROKIT Healthcare believes that supplying an avenue for organ regeneration will drastically change the way that everyday people trust and manage their own body.
- Published in Press Releases
GLOBAL STEM CELLS GROUP ANNOUNCES THE LAUNCH OF ITS NEW DIVISION “VITA NOVAS”
A Step towards the Actualization of Regenerative Medicine
The Global Stem Cells Group takes another luminary step by launching its new company VITA NOVAS in the field of Regenerative medicine. Vita Novas is a mobile IV infusion company that provides in-home treatments to patients in need of immune modulation to help fight infections, viruses, and diseases. Under the banner of GSCG, Vita Novas is ready to launch in 26 countries in the first year of its inception.
Having the cushion of an already established worldwide network and 10 years of experience of GSCG, VITA NOVAS has already gained ground with the inherited reputation of quality, innovation, and professionalism. The VITA NOVAS’ program delivers micronutrients and stimulating biological products like Exosomes and Mesenchymal Stem Cells intravenously, guaranteeing an effective way for the ingredients to become immediately available to the cells. This greatly decreases the time it takes for the medication or supplements to take effect. Patient-centred carved out packages The Shield, the Fighter, and the Lightening are delivered on-demand to homes, offices, or hotels administered by certified healthcare professionals.
Believing on the percept of Prevent-Protect-Thrive, VITA NOVAS aspires to set standards in the industry, and committed to ensure in-home, and personalized patient service; keeping them away from hospitals and emergencies. VITA NOVAS offers infusion packages, mixed with essential fluids, electrolytes, vitamins, and antioxidants as a powerful cocktail to stimulate the immune system and help bolster it to assist in fighting infections and diseases. In-line with the evolved life pattern of social distancing, the process of treatment at VITA NOVAS culminates as:
Select your Service Area
Schedule a video consultation with our local doctors to discuss your possible treatment plan
Receive the treatment at home
“We have combined elements of Tele-health with cellular therapy, IV wellness infusions, and a direct-to-consumer model intending to capitalize on the burgeoning market for medical services at the patient’s’ place of residence, due to convenience and social distancing practices,” explains Benito Novas , CEO of VITA NOVAS.
The secret behind the VITA NOVAS program is the provision of assistance and prime incentives to medical professionals. Once a physician joins the network, the company provides training and support that they will need in order to set-up run, and market their practices. They enjoy geography and specialization exclusively as well as a strong network of patients referrals, increased revenues, and conduct consultations from home.
Global Stem Cells Group, with golden track record and experience of a decade, is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2010 by Benito Novas, the company combines dedicated researchers, physicians, patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading-edge Regenerative Medicine treatments. Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology, while adhering to the highest medical standards.
VITA NOVAS can help, to find your service area, please visit: www.vitanovas.net
To know more about the company , visit www.stemcellsgroup.com
- Published in Press Releases
ISSCA to Conduct First Hands On Regenerative Medicine Training after Global Pandemic
he COVID19 pandemic has brought about a ‘new normal’ of social-distancing, closed businesses and self-isolation. After several months of inactivity brought about by this virus and the period of self-isolation, the International Society for Stem Cell Application is ready to begin the process of resuming our schedule of training courses,
Florida (PRUnderground) May 19th, 2020
Now, more than ever, interest in the immune system and its health has breached our collective consciousness, both phycicians and scientist are turning to regenerative medicine as a way to strengthen it. Recent breakthroughs in the field have led to a newly devised program– one with a proprietary protocol for strengthening the immune system, furthering a person’s ability to fight and prevent disease.
This inaugural training will take place in Washington over the course of two days, during which we will be training a group of five doctors in the latest regenerative medicine techniques. We will go over our traditional program providing physicians with all of the tools they will need to begin incorporating regenerative medicine into their own practice
The International Society for Stem Cell Application is an independent, non-profit organization whose objective is to become the gold standard of regenerative medicine. It accomplishes this through hosting conferences and specialized certification courses, publishing and sharing clinical research, and setting protocols in the field of regenerative medicine. Through this partnership, we are seeking to spread knowledge on the current applications of cellular therapies by building a platform for doctors to discuss and debate the newest advancements in the field. These conferences have been held in dozens of countries, and work to create a global network of regenerative medicine researchers and practitioners.
If you’d like to know more information about our program, or the courses that we offer around the world, please check out by visiting our website at: www.issca.us
About International Society for Stem Cells Applications
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative
medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com
- Published in Press Releases
GLOBAL STEM CELLS GROUP will host ISSCA Regenerative Medicine Training
After several months of silence due to the mandatory shutdown in place, the training division of Global Stem Cells Group –known as ISSCA Training– has officially announced the reopening of its regularly scheduled training dates Around the world
Miami, FL (PRUnderground) May 20th, 2020
“The future’s looking bright for our Regenerative MedicineTraining program, we’ve taken our course and updated it, reinforcing it with new information and quality protocols that’ll help doctors and their patients manage this ‘new normal’ as well as they can, and we’re very excited to be able to be bringing this new information to physicians around the world– but we’ve decided to start small for now, with the reinstatement of our headquarters’ operations,” — Benito Novas, CEO
Because of the growing interest in the industry , ISSCA Regenerative MedicineTraining has updated its program with new protocols focused on the optimization of the body at the cellular level. Notably, their upcoming June course will also include live practice patients in the treatments of autologous cell therapy, which includes PRP, adipose-derived stem cells, bone-marrow derived stem cells, exosomes, Umbilical Cord Blood Cells, and other novel techniques.
Stem Cell Training is a company that seeks to instruct medical professionals around the world on regenerative medicine techniques. They do this by sharing breakthrough scientific research on stem cell therapy and treatment, as well as developing and offering courses, seminars, and workshops based on this research.
About the Global Stem Cells Group:
Global Stem Cells Group is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2010, the company combines dedicated researchers, physicians ,patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge Regenerative Medicine treatments.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology
- Published in Press Releases
Global Stem Cells Group Announces Launch of Vita Novas In-Home IV Infusion Service
Its no secret that a quality IV infusion can boost health and energy. Vita Novas makes this more simple than ever performing IV services than revitalize the body and help it regenerate, right at home.
Miami , Florida (PRUnderground) May 20th, 2020
The interest in boosting the immune system in a safe and effective way is a topic on more minds than ever. In exciting news, Global Stems Group has announced the launch of a new company, Vita Novas who make this both simple and dependable. Vita Novas offers an IV infusion packages are a mix of stem cells, essential fluids, electrolytes, vitamins and antioxidants as a preventive solution for having an optimal immune system. This IV infusion is delivered at home, in an office, or at a hotel, by certified healthcare professionals. With the global pandemic shutting doors of physicians for elective and health-enhancing non-vital procedures going to get IV treatments in most communities is difficult, if not impossible. Vita Novas is opening the doors for these life-enhancing treatments to be accesses in an easy and convenient way.
“The demand for preventive health services using IV infusion is greater than ever,” commented Benito Novas, CEO of the company. “What we are doing, by offering these at home and offices, is not just making things more convenient but also following social distancing requirements. Its truly making the right thing available at the right time and place.”
Vita Novas provides a teleconsultation with a Doctor to determine what meets a patient’s needs best. Three different vitamin and nutrient vitamin infusion packages are available.
The Lighting Package consists of two sessions of IV administration of vitamins (Vitamin C, B-Complex vitamins, and trace minerals), with a patient follow up recommending dietary changes and oral supplements to maintain good health.
The Shield Package is three sessions of IV administered (high dose Vitamin C, Methylcobalamin, Zinc sulphate, Glutathione and five billion flow exosomes). This has been shown have a powerful effect in regulating regenerative processes in the body and increase cell to cell communication. This has been used to treat COVID-19 patients with exciting results, something clearly at the front of people’s minds of all ages and lifestyles.
The Fighter Packages is the platinum offer from Vita Novas. This combines IV administration of high dose micronutrients (amino acids, glutathione), vitamins (B-Complex, methylcobalamin, Folic Acid, Vitamin C), and trace minerals (zinc, copper, magnesium) along with 30 million live stem cells in 5 sessions. This can modulate immunity and assist in the regeneration process of damaged or infected tissue in a very dramatic way.
Vita Novas is currently positioned to be able to launch the program in ten different countries with the number rising to over 25 within six months. The near and far future are bright for the company and its potentially life-changing services.
About the Global Stem Cells Group:
Global Stem Cells Group is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2010, the company combines dedicated researchers, physicians ,patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge Regenerative Medicine treatments.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology
- Published in Press Releases
Cellgenic Set to Open New Stem Cells Center in Belgium through Partnership with Churchill Aesthetic Center
The subsidiary of the Global Stem Cells Group seeks to meet the growing demand for patients seeking stem cells treatments across the globe.
MIAMI LAKES, Florida— Cellgenic, a subsidiary of the Global Stem Cells Group (GSCG), has announced that it has signed an agreement that will bring regenerative medical treatments to more patients across Europe with the opening of a new stem cells treatment center in Belgium.
The agreement, signed between the GSCG and Dr. Samy Joheir, owner of Churchill Aesthetic Center (https://www.churchill-aesthetic-center.be/), expands the GSCG’s mission of expanding access to regenerative medicine globally. The agreement opens the center’s doors to patients seeking stem cells treatment options and to physicians across Europe and the Middle East seeking educational opportunities regarding how to incorporate regenerative medicine into their practices. The center is located at 141 Winston Churchill Avenue, B-1180 in Brussels.
The Brussels center will also serve as the GSCG’s head offices and will help the group better serve patients and doctors across Europe and the Middle East.
To new center will officially open on September 30, 2019. In conjunction with the center’s opening, the GSCG and Dr. Joheir will welcome three patients from the Middle East seeking treatments offered by the center. These patients were previously treated in the US prior to the institution of stricter FDA stem cells regulations. The Belgium center will provide these patients with treatment options closer to home, alleviating emotional, financial, and physical stressors in receiving treatment, similar to the group’s current facilities in Cancun that provide critical stem cells treatment to patients traveling from the US.
With the opening of the center, the GSCG also aims to provide more accessible educational facilities and options for physicians in the region looking to receive training in regenerative medicine. The training is in alignment with the services currently offered at the GSCG’s other facilities, such as those located in Cancun for physicians across the Americas.
Over the past few years, the GSCG has sought to achieve its mission in helping to alleviate human suffering by opening stem cells centers across the globe to meet growing patient demands. All of the group’s centers are all currently located outside of the US due to current FDA regulations restricting regenerative medicine products and protocols.
“The Global Stem Cells Group is pleased to be able to reach more patients seeking relief through regenerative medicine with the opening of our Belgian center,” said Benito Novas, CEO of the Global Stem Cells Group. “This expansion will help alleviate travel and financial barriers some European and Middle Eastern patients face in receiving the care they need, now providing them access to a facility closer to home. We are committed to opening up additional treatment centers for both physicians and patients across the globe who may be limited by their local regulations in accessing critical stem cells therapies. Through our facilities, patients looking for relief from regenerative diseases will receive top-notch care in state-of-the-art facilities.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Global Stem Cells Group Set to Conduct Clinical Trials in Miami
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, announced its participation in a new clinical trial in Miami. The trial is sponsored by InGeneron, Inc. and will provide researchers the opportunity to compare two treatment options in patients with partial-thickness rotator cuff tears (PTRCTs). Patient groups will be injected either with a single injection of adipose-derived regenerative cells (ADRCs) or a single corticosteroid injection to examine the efficacy of both treatment protocols.
The study is a prospective, double-blinded, randomized, active-controlled, multi-site, pivotal safety and superior effectiveness study in patients with symptomatic partial-thickness rotator cuff tears. Researchers will compare a single ADRC injection generated with the Transpose® RT system into the supraspinatus tendon and surrounding area to standard-of-care (SOC) corticosteroid injection into the subacromial bursa.
Up to 20 U.S. centers will be initiated to enroll in the study. Two hundred and forty six subjects will be assigned to two randomization arms: an adipose-derived regenerative cell (ADRC) injection arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All subjects will be randomly assigned to the ADRC treatment or active control arms in a 2:1 ratio.
The GSCG clinical trial is registered with the US Food and Drug Administration (FDA) and will adhere to all FDA safety protocols. The GSCG will help recruit patients for the study. The goal of the trial is to demonstrate the safety and efficacy of stem cells treatments in helping to treat patients suffering from degenerative diseases and injuries such as PTRCTs.
“The Global Stem Cells Group is committed to helping people across the globe find relief from debilitating diseases and is pleased to serve as a leader in cutting-edge research in the stem cells field,” said Benito Novas, CEO of the Global Stem Cells Group. “This clinical trial will hopefully help us achieve these goals by demonstrating the safety and efficacy of regenerative medicine treatments to physicians, patients, and regulatory bodies so that more patients are able to have access to these treatment protocols and find relief.”
To learn more about the clinical trial, visit https://clinicaltrials.gov/ct2/show/NCT03752827. To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Lans Holdings Secures Extension to Complete Acquisition of Global Stem Cells Group
MIAMI, FL, Sept. 11, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Lans Holdings Inc. is pleased to announce that it has successfully secured a 180-day extension to complete the acquisition of 100% of Global Stem Cells Group Inc (GSCG).
On Friday September 6, 2019, trading in the company’s stock was suspended due to a missed communication regarding the pending delinquent annual filings. Company management has had several discussions with the SEC and has determined that an old address is the cause for the missing paperwork. The Company has agreed to enter into a settlement with the SEC, which will result in the deregistering of the Company’s shares. Company management had been working with its auditors, accounting staff and outside consultants for the past few months to bring the Company’s filings current when the Company learned of the revocation. The Company intends to now file a form 10 to reregister its common shares with the SEC and to locate a market maker to sponsor the Company in a 211 filing to reinstate trading of the Company’s shares.
“We regret the concern this put on the market, and especially the delay in communication of these events, as we had to ensure that we had accurately secured all of the necessary agreements to successfully recover from this disruption,” said Dave Christensen, CEO of Lans Holdings. “We have been working diligently on catching up all records and we are looking forward to quickly submitting a Form 10, and then closing the acquisition.”
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
- Published in Press Releases
The FDA Vs Stem Cell Treatments In The US
Introduction
Stem cell therapy has become a popular type of treatment for a number of conditions, including the regeneration of injured tissue or diseased cells in the human body. This therapy is classified as regenerative medicine. Several advancements have already been made in this medical field, and many have experienced positive results when they underwent stem cell therapy to assist in the treatment of degenerative conditions.
Benefits and Concerns of Stem Cell Therapy
While stem cell therapy has been proven to provide an effective protocol in the recovery of stroke, neurological issues, and even to assist in repairing the damage caused by a heart attack, recent reports have caused many to view these treatments negatively. This is due to warnings that were recently issued by the FDA. Even though some have experienced side effects due to the use of stem cell therapy, it is important to note that there are facilities within the US that can provide professional services that help to minimize the risk of these adverse events.
The FDA’s Stance on Stem Cell Therapy in the United States
The Food and Drug Administration of the United States is involved in analyzing and approving medications and medical procedures that may be offered to patients in the country. To date, the FDA has shown some interest in stem cell therapy, providing approval for several clinical trials that looked at how effective this treatment is in providing a regenerating effect on the impact that certain conditions have on the human body. However, only one particular treatment involving stem cell therapy has been officially approved by the FDA.
Recent FDA Actions and Their Impact
Within the last few months, several concerning publications have been made by the FDA regarding stem cell therapies, reducing the hope that some patients might have gained. On June 25, 2019, the FDA published a statement describing a permanent injunction against many stem cell clinics in the country. The FDA stated that the action taken from their side is to assist in providing a layer of protection for patients, due to the risks involved with undergoing treatments that utilize products that have not gone through any type of approval process.
The Case Against US Stem Cell Clinic LLC
The specific company targeted in this statement and by the actions taken by the FDA is known as US Stem Cell Clinic LLC. The court ruled in favor of the FDA and US government earlier in June, finding the defendants, being US Stem Cell Clinic LLC, guilty of the claims made against them. An earlier publication also confirmed that the Federal court ruled the misbranding of the stem cell products released by the US Stem Cell Clinics company as a violation of laws implemented to protect the people of the country.
Implications of FDA Regulations on Stem Cell Treatments
News publications have announced that the regulations and guidelines set out by the FDA might cause a significant decline in the availability of stem cell treatments to patients in the United States. The companies targeted by these particular actions are primarily those marketing products that have not gone through approval phases – and these products have been found to put the patient’s health at risk.
The Role of Stem Cell Therapy in Disease Treatment
While some companies have been found guilty of using unapproved and misleading products on patients, promoted as stem cell therapy, it is important to consider the reality of the situation as well. Stem cell therapy, often referred to simply as cell therapy, has been proven to be a successful regime in the treatment of several conditions. Many of the conditions that have shown improvement with this therapy were previously considered difficult, or sometimes even impossible, to treat effectively.
Global Success of Stem Cell Therapy
By 2012, the Worldwide Network for Blood and Marrow Transplantation (WBMT) announced that a total of one million stem cell therapy procedures had been done throughout the world. This was a significant milestone, and these procedures have helped to save countless lives. The WBMT refers to a case of Marta, a girl from Madrid, who received stem cell therapy at a young age after being diagnosed with Leukemia. In 2002, Marta was able to overcome Leukemia, thanks to the cell therapy provided to her.
Expanding Applications of Stem Cell Therapy
While lymphoma and leukemia are the conditions where patients most frequently seek stem cell therapy, many other conditions are treated with this procedure today. The perfection of the therapy has led to treatments that can assist in reducing the effects of over 70 diseases that may otherwise have a significant impact on the human body.
GSCG Expands to Cancun, Meets the Demands of US Patients
The Global Stem Cells Group recently announced the opening of a new office in Cancun, Mexico. This decision was driven by the increasing demand for cell therapy procedures by patients in the United States and the lack of facilities able to provide these individuals with professional and quality services. Doctors specializing in regenerative medicine are also having a hard time fulfilling the needs of patients who wish to consider cell therapy as a potential treatment option.
GSCG’s Facilities in Cancun
This is not the only local office that GSCG operates in Cancun, as the company now has two facilities within this location. These offices include a stem cells laboratory and a general medical facility. Over the years, GSCG has become an established name in the stem cell field, providing thousands of doctors the opportunity to offer cell therapy as a treatment option for patients with degenerative diseases. This therapy may assist in the regeneration of damaged and diseased tissues in the patient’s body.
Ensuring Quality and Safety at GSCG
Even though a previous office had established a presence for GSCG in Cancun, the company announced that the opening of the new office means they have now officially created a permanent presence for the brand in the area. GSCG’s new facility in Cancun is equipped with the latest advancements in the field and provides quality services that ensure patients have a trusted medical facility where they can undergo cell therapy as part of a regenerative medicine treatment plan.
Support for US Doctors in Regenerative Medicine
Doctors in the field of regenerative medicine within the United States can now turn to this facility to offer their patients an additional treatment option, apart from the standard pharmaceutical protocols. The stem cell laboratory can assist in analyzing patient data and finding a matching donor for those in need of stem cell treatment. GSCG’s facility can help with the culturing of expanded autonomous cells and other cell types utilized in stem cell therapy. A detailed approach is taken, considering the age of the donor, which provides an overview of the autonomous stem cell age. The patient being treated is also closely considered, as there are different methods of introducing these stem cells to the body for enhanced efficacy.
Advanced Treatment Methods at GSCG
A more aggressive method is often needed for patients with conditions such as autism, Alzheimer’s disease, and kidney-related conditions. Other conditions treated include pulmonary diseases and Parkinson’s disease. In cases of stroke, the vascular arteries, along with the carotid artery, are targeted with the therapy for a more effective approach to assisting with the regeneration of damaged structures in the patient’s brain. This ultimately leads to a significant improvement in the delivery of stem cells to the patient’s body, enhancing the overall efficacy of the treatment.
Comprehensive Patient Care at GSCG
When procedures are provided to the patient through the GSCG, an appropriate ICU unit is made available to ensure the patient is provided with adequate care during the operation and recovery. The utilization of recent technological advancements at GSCG laboratories can also assist in providing a more economical approach to cell therapy. Allogenic stem cell procedures can be addressed using techniques that reduce the costs involved, making these treatments available to patients at a lower price.
Advanced Cultivation Techniques at GSCG
The utilization of autologous stem cell transplantation offers an opportunity for patients to undergo stem cell therapy when a sibling does not provide an ideal match. Cells can be cultivated from the bone marrow and treated with specific drugs to yield targeted results. In the case of malignant cells, bone marrow can be treated with monoclonal antibodies or cytotoxic drugs to target such cells when transplanted back into the patient. Appropriate storage solutions are also considered to assist with the cultivation process and reduce the risk of enzymatic treatment leading to the differentiation of cells into other types. The culture condition becomes crucial for the expansion of stem cells, utilizing mediums and techniques that ensure successful cultivation and expansion.
The GSCG’s Role in the New FDA Warnings
The FDA’s recent warnings and actions against certain stem cell therapy products have caused a limitation in access to these treatments. With the seizure of services provided by companies affected by the FDA’s actions, patients may not be sure where to turn. This issue also affects many doctors in regenerative treatments and medicine, as they need to ensure that the facilities they use for patients offer safe procedures.
GSCG’s Trusted Services
This is where the GSCG comes into the picture. With an established presence in Mexico, doctors now have access to a facility with a history of providing quality stem cell therapy services to patients with qualifying diseases. The company is trusted and has performed stem cell therapy procedures that have led to successful results.
Hope for Patients Through GSCG
These treatments may help repair neurological problems caused by disorders like Parkinson’s disease, stroke, or spinal cord injuries. They may also offer new hope to people with diabetes, heart disease, and those who have suffered cardiovascular damage due to a heart attack.
Conclusion
Even though recent FDA publications have raised concerns regarding stem cell therapy, many patients are still interested in undergoing these treatment procedures. A significant number of studies have provided evidence on the efficacy of treating tissue damage caused by various conditions through stem cell therapy. Patients interested in undergoing stem cell treatment are now advised to turn their interest to Stem Cells Centers in Cancun and related regions, where highly specialized and experienced doctors can provide professional service.
- Published in Corporate News / Blog
